CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients

Shi, Wei-Lin; Li, Jian; Du, Yong-Jie; Zhu, Wen-Fang; Wu, Yan; Hu, Yi-Ming; Chen, Yong-Chang
December 2013
Medical Oncology;Dec2013, Vol. 30 Issue 4, p1
Academic Journal
No abstract available.


Related Articles

  • Small-cell lung cancer in elderly patients: The case for chemotherapy. Kelly, P.; O'Brien, A.A.J. // Age & Ageing;Jan1991, Vol. 20 Issue 1, p19 

    Details a retrospective analysis of survival in 48 elderly and 70 young patients with small-cell lung cancer. Similar survivability with combination chemotherapy with old and young subjects; Peripheral neuropathy secondary to vincristine and elderly subjects; Small-cell lung cancer and smoking;...

  • Survival after treatment of small-cell lung cancer: an endless uphill battle. Glisson, Bonnie S.; Hong, Waun K.; Glisson, B S; Hong, W K // JNCI: Journal of the National Cancer Institute;12/03/97, Vol. 89 Issue 23, p1745 

    Editorial. Focuses on the association of tobacco exposure with small-cell lung cancer (SCLC). Treatment of SCLC; Prospects for SCLC patient survival; Evidence supporting the association of lung cancer with tobacco exposure.

  • Increasing Chemotherapy in Small-Cell Lung Cancer: From Dose Intensity and Density to Megadoses. Crivellari, Gino; Monfardini, Silvio; Stragliotto, Silvia; Marino, Dario; Aversa, Savina Maria Luciana // Oncologist;Jan2007, Vol. 12 Issue 1, p79 

    The hypothesis that increasing cytotoxic dose intensity will improve cancer cure rates is compelling. Although supporting evidence for this hypothesis has accrued for several tumor types, including lymphomas, breast cancer, and testicular cancers, it remains unproven. Small-cell lung cancer is...

  • Small-Cell Carcinoma of the Lung: therapeutic Management. Weiss, Raymond B. // Annals of Internal Medicine;Apr78, Vol. 88 Issue 4, p522 

    Provides information on the treatment methods for small-cell lung cancer. Result of surgery in patients; Efficacy of radiotherapy; Details on studies of chemotherapy-alkylating agents; Advantage of vincristine; Conclusions.

  • Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. Pujol, Jean-Louis; Daures, Jena-Pierre; Riviere, Alain; Quoix, Elisabeth; Westeel, Virginie; Quantin, Xavier; Breton, Jean-Luc; Lemarie, Etiene; Poudenx, Michel; Milleron, Bernard; Moro, Denis; Debieuvre, Didier; Le Chevalier, Thierry; Pujol, J L; Daurès, J P; Rivière, A; Quoix, E; Westeel, V; Quantin, X; Breton, J L // JNCI: Journal of the National Cancer Institute;02/21/2001, Vol. 93 Issue 4, p300 

    Background: The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC). To determine whether drug intensification improves survival of patients with extensive SCLC, we compared this treatment with a four-drug regimen...

  • Epidemiology.  // Thorax;Dec2013 Supplement, Vol. 68 Issue S3, pA80 

    The article presents abstracts on lung cancer epidemiology which include "Small-Cell Lung Cancer In England: Trends In Survival And Therapy" , "Identifying Patients Who Receive Chemotherapy For Small-Cell Lung Cancer Using Large Dataset" and treated asthma patients' burden on Great Britain...

  • Chemoradiotherapy for Limited-disease Small-cell Lung Cancer in Elderly Patients Aged 75 Years or Older. Shukuya, Takehito; Takahashi, Toshiaki; Harada, Hideyuki; Ono, Akira; Akamatsu, Hiroaki; Taira, Tetsuhiko; Kenmotsu, Hirotsugu; Naito, Tateaki; Murakami, Haruyasu; Endo, Masahiro; Takahashi, Kazuhisa; Yamamoto, Nobuyuki // Japanese Journal of Clinical Oncology;Feb2013, Vol. 43 Issue 2, p176 

    Background As clinical trials for limited-disease small-cell lung cancer often exclude elderly patients due to comorbidities and a decline in organ function, the most suitable treatment for limited-disease small-cell lung cancer patients aged 75 years or older still remains unclear. Methods From...

  • Staging lung cancer.  // British Medical Journal;7/12/1980, Vol. 281 Issue 6233, p94 

    Focuses on the significance of staging in management of patients with lung cancer. Treatment of lung cancer; Information on the staging procedures; Importance of re-staging in small-cell cancer; Choice of systems of nomenclature for lung cancer.

  • Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Johnson, Bruce E.; Ihde, Daniel C.; Bunn, Paul A.; Becker, Bruce; Walsh, Thomas; Weinstein, Zelig R.; Matthews, Mary J.; Whang-Peng, Jacqueline; Makuch, Robert W.; Johnston-Early, Anita; Lichter, Allen S.; Carney, Desmond N.; Cohen, Martin H.; Glatsten, Eli; Minna, John D.; Johnson, B E; Ihde, D C; Bunn, P A; Becker, B; Walsh, T // Annals of Internal Medicine;Sep85, Vol. 103 Issue 3, p430 

    We assessed the outcome in 252 patients with small-cell lung cancer 5 to 11 years after treatment with combination chemotherapy, with or without chest and cranial irradiation, in National Cancer Institute therapeutic trials from 1973 through 1978. Twenty-eight patients (11%) survived free of...

  • Irinotecan in Extensive Disease Small-Cell Lung Cancer--Impact on European Patients. Hermes, Andreas // European Journal of Clinical & Medical Oncology;2010, Vol. 2 Issue 3, p1 

    In extensive disease small-cell lung cancer, treatment outcome has not changed much during the last 30 years with an overall survival between 8 and 10 months. Several classes of new drugs are now available for patients with non-small cell lung cancer, but to date, there is no comparable efficacy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics